The landscape of chimeric antigen receptor (CAR) T-cell therapy continues to evolve at a remarkable pace. Since the first FDA approval in 2017, the therapeutic indications for CAR T-cell products have expanded considerably across hematological neoplasms and beyond malignancies. This rapid application of CAR T-cell therapies stipulates the need of deepening the understanding, detection and management of CAR T-cell driven toxicities such as neurological complications.
